Table I.
Demographics, co-morbidities, and pre-operative lesion characteristics between 1,294 patients with insulin-dependent diabetes, noninsulin-dependent diabetes, and no diabetes with chronic limb-threatening ischemia (CLTI)
| IDDM | NIDDM | NDM |
P -value (IDDM to NIDDM) |
P -value (IDDM to NDM) |
P -value (NIDDM to NDM) |
P-value | |
|---|---|---|---|---|---|---|---|
| (N=703) | (N=262) | (N=329) | |||||
| Demographics No. (%) | |||||||
| Age, mean (SD) | 68.9 (12.0) | 72.9 (11.0) | 76.6 (12.5) | <.001 | <.001 | <.001 | <.001 |
| Race | 0.03 | <.001 | 0.04 | <.001 | |||
| White | 518 (74) | 210 (81) | 286 (87) | ||||
| Non-white | 182 (26) | 50 (19) | 43 (13) | ||||
| Male sex | 436 (62) | 148 (57) | 185 (56) | .13 | .08 | .91 | .13 |
| Indication, No. (%) | |||||||
| Rest Pain | 78 (11) | 59 (23) | 108 (33) | <.001 | <.001 | <.01 | <.001 |
| Ulcer | 407 (58) | 124 (47) | 148 (45) | <.01 | <.001 | .57 | <.001 |
| Gangrene | 218 (31) | 79 (30) | 73 (22) | .80 | <.01 | .03 | .01 |
| Comorbidities, No. (%) | |||||||
| Coronary artery disease | 395 (57) | 123 (48) | 136 (43) | .01 | <.001 | .27 | <.001 |
| Hypertension | 622 (89) | 226 (87) | 242 (76) | .47 | <.001 | .001 | <.001 |
| Hyperlipidemia | 466 (67) | 145 (56) | 167 (53) | <.01 | <.001 | .43 | <.001 |
| Dialysis dependence | 185 (26) | 34 (13) | 38 (12) | <.001 | <.001 | .67 | <.001 |
| BMI, mean | 29.0 | 27.6 | 24.5 | <.01 | <.001 | <.001 | .04 |
| History of myocardial infarction | 215 (31) | 65 (25) | 54 (17) | .09 | <.001 | .02 | <.001 |
| Congestive heart failure | 234 (34) | 73 (28) | 88 (28) | .12 | .06 | .89 | .10 |
| COPD | 69 (10) | 23 (8.9) | 60 (19) | .66 | <.001 | .001 | <.001 |
| Smoking history | 401 (57) | 150 (58) | 220 (69) | .88 | <.001 | <.01 | .001 |
| WIfI clinical stage,16 No. (%) | |||||||
| Clinical stage 1 | 6 (1.2) | 2 (1.0) | 3 (1.2) | .85 | .98 | .85 | .98 |
| Clinical stage 2 | 99 (19) | 65 (33) | 116 (46) | <.001 | <.001 | <.01 | <.001 |
| Clinical stage 3 | 140 (27) | 48 (24) | 56 (22) | .37 | .13 | .66 | .28 |
| Clinical stage 4 | 268 (52) | 85 (43) | 77 (31) | .02 | <.001 | <.01 | <.001 |
| Fempop TASC classification, No. (%) | |||||||
| TASC A | 120 (19) | 50 (22) | 42 (15) | .49 | .11 | .05 | .13 |
| TASC B | 185 (30) | 78 (34) | 82 (29) | .30 | .83 | .28 | .50 |
| TASC C | 76 (12) | 30 (13) | 44 (16) | .80 | .17 | .38 | .38 |
| TASC D | 104 (17) | 44 (19) | 88 (31) | .46 | <.001 | .001 | <.001 |
| Tibial TASC classification, No. (%) | |||||||
| TASC A | 78 (13) | 30 (13) | 35 (13) | .83 | .97 | .87 | .98 |
| TASC B | 143 (23) | 46 (20) | 55 (20) | .36 | .29 | .95 | .46 |
| TASC C | 138 (23) | 50 (21) | 55 (20) | .91 | .43 | .58 | .72 |
| TASC D | 198 (32) | 66 (29) | 87 (32) | .40 | .89 | .53 | .70 |
IDDM, insulin-dependent diabetes; NIDDM, noninsulin-dependent diabetes; NDM, non-diabetes; COPD, chronic obstructive pulmonary disease; WIfI, wound, ischemia, and foot infection; TASC, Trans Atlantic Inter-society Consensus